{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:58:52Z","timestamp":1783130332209,"version":"3.54.6"},"reference-count":32,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.3892\/or.2013.2682","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T07:32:22Z","timestamp":1377070342000},"page":"2481-2487","source":"Crossref","is-referenced-by-count":25,"title":["Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer"],"prefix":"10.3892","volume":"30","author":[{"given":"LUCIA","family":"MANGANARO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SIMONA","family":"MICHIENZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VALERIA","family":"VINCI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RENATO","family":"FALZARANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATTEO","family":"SALDARI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TERESA","family":"GRANATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VALENTINA","family":"VIGGIANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LUIGI","family":"FRATI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EMANUELA","family":"ANASTASI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"key":"key20180107223553_b1-or-30-05-2481","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1158\/1055-9965.EPI-12-0646","article-title":"Biomarkers for screening, diagnosis, and monitoring of ovarian cancer","volume":"21","author":"Kobayashi","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 2","key":"key20180107223553_b2-or-30-05-2481","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S0020-7292(12)60025-3","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"119","author":"Berek","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"key":"key20180107223553_b3-or-30-05-2481","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2010.09.002","article-title":"Status of tumor markers in epithelial ovarian cancer has there been any progress?","volume":"120","author":"Husseinzadeh","year":"2011","journal-title":"A review Gynecol Oncol"},{"key":"key20180107223553_b4-or-30-05-2481","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"Suppl 3","key":"key20180107223553_b5-or-30-05-2481","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1525-1438.2005.00441.x","article-title":"New tumor markers: CA125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"key20180107223553_b6-or-30-05-2481","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejogrb.2008.08.011","article-title":"Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review","volume":"142","author":"Medeiros","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20180107223553_b7-or-30-05-2481","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1530\/ror.0.0030086","article-title":"Molecular characterization of epididymal proteins","volume":"3","author":"Kirchhoff","year":"1998","journal-title":"Rev Reprod"},{"key":"key20180107223553_b8-or-30-05-2481","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"key20180107223553_b9-or-30-05-2481","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107223553_b10-or-30-05-2481","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erm.09.39","article-title":"HE4 as a biomarker for ovarian and endometrial cancer management","volume":"9","author":"Li","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"key20180107223553_b11-or-30-05-2481","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"key20180107223553_b12-or-30-05-2481","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/CCO.0b013e32833c3351","article-title":"Current clinical use of biomarkers for epithelial ovarian cancer","volume":"22","author":"Moore","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"key20180107223553_b13-or-30-05-2481","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1148\/radiology.215.3.r00jn25761","article-title":"Staging of advanced ovarian cancer: comparison of imaging modalities - report from the Radiological Diagnostic Oncology Group","volume":"215","author":"Tempany","year":"2000","journal-title":"Radiology"},{"key":"key20180107223553_b14-or-30-05-2481","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2004.10.028","article-title":"Should CA-125 response criteria be preferred to Response Evaluation Criteria In Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?","volume":"22","author":"Gronlund","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180107223553_b15-or-30-05-2481","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"issue":"Suppl 4","key":"key20180107223553_b16-or-30-05-2481","doi-asserted-by":"crossref","first-page":"L87","DOI":"10.1007\/s00330-003-1964-y","article-title":"Ovarian cancer: the clinical role of US, CT, and MRI","volume":"13","author":"Togashi","year":"2003","journal-title":"Eur Radiol"},{"key":"key20180107223553_b17-or-30-05-2481","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(07)70273-5","article-title":"Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations","volume":"8","author":"Goonewardene","year":"2007","journal-title":"Lancet Oncol"},{"issue":"Suppl 4","key":"key20180107223553_b18-or-30-05-2481","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/annonc\/mdp117","article-title":"Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Aebi","year":"2009","journal-title":"Ann Oncol"},{"key":"key20180107223553_b19-or-30-05-2481","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"issue":"Suppl 10","key":"key20180107223553_b20-or-30-05-2481","doi-asserted-by":"crossref","first-page":"s200","DOI":"10.1200\/JCO.2003.01.068","article-title":"Status of tumor markers in ovarian cancer screening","volume":"21","author":"Bast","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107223553_b21-or-30-05-2481","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs. the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"key20180107223553_b22-or-30-05-2481","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2011.11.050","article-title":"Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125","volume":"125","author":"Schummer","year":"2012","journal-title":"Gynecol Oncol"},{"key":"key20180107223553_b23-or-30-05-2481","doi-asserted-by":"crossref","first-page":"109ra116","DOI":"10.1126\/scitranslmed.3003110","article-title":"Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations","volume":"3","author":"Hori","year":"2011","journal-title":"Sci Transl Med"},{"key":"key20180107223553_b24-or-30-05-2481","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00432-013-1432-2","article-title":"p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer","volume":"139","author":"H\u00e4fner","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl 8","key":"key20180107223553_b25-or-30-05-2481","doi-asserted-by":"crossref","first-page":"viii45","DOI":"10.1093\/annonc\/mdr471","article-title":"Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed","volume":"22","author":"Rustin","year":"2011","journal-title":"Ann Oncol"},{"key":"key20180107223553_b26-or-30-05-2481","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"key":"key20180107223553_b27-or-30-05-2481","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00330-010-1886-4","article-title":"ESUR guidelines: ovarian cancer staging and follow-up","volume":"20","author":"Forstner","year":"2010","journal-title":"Eur Radiol"},{"key":"key20180107223553_b28-or-30-05-2481","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1148\/radiol.2232011081","article-title":"Peritoneal metastases: detection with spiral CT in patients with ovarian cancer","volume":"223","author":"Coakley","year":"2002","journal-title":"Radiology"},{"key":"key20180107223553_b29-or-30-05-2481","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1148\/radiol.10092279","article-title":"Recurrent ovarian cancer: use of contrast-enhanced CT and PET\/CT to accurately localize tumor recurrence and to predict patients\u2019 survival","volume":"257","author":"Sala","year":"2010","journal-title":"Radiology"},{"key":"key20180107223553_b30-or-30-05-2481","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijgo.2009.11.021","article-title":"Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer","volume":"109","author":"Diniz Bizzo","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"key20180107223553_b31-or-30-05-2481","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3802\/jgo.2011.22.4.299","article-title":"The role of neoadjuvant chemotherapy in ovarian cancer patients with extensive tumor burden","volume":"22","author":"Kang","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"key20180107223553_b32-or-30-05-2481","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s13277-012-0376-5","article-title":"HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma","volume":"33","author":"Midulla","year":"2012","journal-title":"Tumour Biol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2682\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T08:45:29Z","timestamp":1596357929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,8,21]]},"published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.3892\/or.2013.2682"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2682","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]}}}